<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03517631</url>
  </required_header>
  <id_info>
    <org_study_id>KL1702</org_study_id>
    <nct_id>NCT03517631</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of shRNA-modified CD34+ Cells in HIV-infected Patients.</brief_title>
  <official_title>A Pilot Study to Evaluate Efficacy and Safety of Multiplexed shRNA-modified CD34+ Cells in HIV-infected Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kanglin Biotech (Hangzhou) Co. LTD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Public Health Clinical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of autologous CD34+ cells
      that stably express multiplexed shRNA to treat HIV infection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CD34+ cells will be isolated from mobilized PBMC of HIV patients. The cells will be
      lentivirally transduced with multiplexed shRNAs in the same vector that target CCR5 and HIV
      genome. Such modified cells will be infused back to the patients who have received bulsufan
      preconditioning before infusion. The patients will then be evaluated for efficacy and safety.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2018</start_date>
  <completion_date type="Anticipated">January 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Infusion of autologous CD34+ cells transduced with shRNAs targeting CCR5 and HIV genome</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse side effects</measure>
    <time_frame>18 months</time_frame>
    <description>Patients will be monitored for any signs of adverse effects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of treatment</measure>
    <time_frame>18 months</time_frame>
    <description>Evaluate the efficacy of modified autologous CD34+ cells by monitoring CD4 counts and HIV-1 RNA level.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>HIV Infections</condition>
  <condition>AIDS</condition>
  <arm_group>
    <arm_group_label>No busulfan preconditioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>shRNA-modified CD34+ cells without busulfan preconditioning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose busulfan preconditioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>shRNA-modified CD34+ cells, with a single dose of 1 mg/kg busulfan administered every 6 hours for 4 times as preconditioning for transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose busulfan preconditioning</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>shRNA-modified CD34+ cells, with a single dose of 1 mg/kg busulfan administered every 6 hours for 8 times as preconditioning for transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>shRNA-modified CD34+ cells</intervention_name>
    <description>Infusion of CD34+ cells transduced with shRNAs.</description>
    <arm_group_label>No busulfan preconditioning</arm_group_label>
    <arm_group_label>Low dose busulfan preconditioning</arm_group_label>
    <arm_group_label>High dose busulfan preconditioning</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose busulfan preconditioning</intervention_name>
    <description>A single dose of 1 mg/kg busulfan administered every 6 hours for 4 times as preconditioning for transplantation.</description>
    <arm_group_label>Low dose busulfan preconditioning</arm_group_label>
    <other_name>Busulfex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan preconditioning</intervention_name>
    <description>A single dose of 1 mg/kg busulfan administered every 6 hours for 8 times as preconditioning for transplantation.</description>
    <arm_group_label>High dose busulfan preconditioning</arm_group_label>
    <other_name>Busulfex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) from 18 - 25; body weight ≥50kg.

          -  Diagnosis of HIV infections/AIDS based on &quot;Diagnostic Criteria for HIV/AIDS&quot; WS
             293-2008.

          -  No antiretroviral therapy (ART) in the past 6 weeks.

          -  CD4 T cell count ≥350/μl.

          -  No plan for pregnancy in the near future and agree to practice non-drug based
             contraception.

          -  Voluntary to participate in the study, comply with the study design to complete all
             monitory measurements, and agree to sign the study agreement.

        Exclusion Criteria:

          -  Existence of infections/opportunistic tumors.

          -  Mutations in the shRNA target sequences.

          -  White blood cell count &lt;3x10^9/L, neutrophil count &lt;1.5x10^9/L, hemoglobin &lt;110g/L,
             platelet count &lt;100x10^9/L.

          -  Liver diseases (HBV, chronic HCV infection, congenital liver metabolic disease),
             abnormal liver functions (test value 2x above normal).

          -  Kidney deficiency (Creatinine level above the upper limit of normal levels).

          -  Severe chronic disease, metabolic disease (e.g., diabetes), neurological and
             psychiatric diseases.

          -  History of pancreatitis.

          -  Women in pregnancy, lactating or at reproductive age who do not practice
             contraception.

          -  Allergy to agents or drugs used in the study.

          -  Verified or suspected abuse of alcohol and drugs.

          -  Participated in other clinical trials within 3 months.

          -  Based on investigator's assessment, those who are unfit for the study (e.g., general
             weakness, poor compliance with study design).

          -  Personal or family history of tumors.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hongzhou Lu, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Caolang Road NO. 2901, Jinshan District, Shanghai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongzhou Lu, M.D., Ph.D</last_name>
    <phone>+86-021-37990333</phone>
    <phone_ext>3222</phone_ext>
    <email>luhongzhou@fudan.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Liu, M.D., Ph.D</last_name>
    <phone>86-021-37990333</phone>
    <phone_ext>3222</phone_ext>
    <email>liulishaphc@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201508</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Liu, Ph.D</last_name>
      <phone>86-021-37990333</phone>
      <phone_ext>3222</phone_ext>
      <email>liulishaphc@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2018</study_first_submitted>
  <study_first_submitted_qc>May 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2018</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Public Health Clinical Center</investigator_affiliation>
    <investigator_full_name>Hongzhou Lu</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>AIDS</keyword>
  <keyword>Lentivirus</keyword>
  <keyword>shRNA</keyword>
  <keyword>Multiplex</keyword>
  <keyword>Gene therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

